Stage 2 of 4
Retatrutide trials and access
Clinical trials, expanded access, and their requirements.
Retatrutide is investigational. It is not sold by any pharmacy, it cannot be compounded, and no telehealth service can prescribe it. Access information below includes clinical trials, expanded access, and the approval timeline, with links to Lilly and ClinicalTrials.gov.
The three routes
- Route 1
Join a clinical trial
Free drug under medical monitoring, with a placebo arm in most studies. Enrollment for most of the Phase 3 program has closed; the live list below shows what is still open.
How trial sign-up works → - Route 2
Ask about expanded access
Since August 3, 2026, a clinician can request retatrutide from Lilly for an adult with refractory obesity and a BMI of at least 35 kg/m², at least two serious complications, and no eligible trial. Case by case, not guaranteed.
Read the criteria → - Route 3
Wait for approval
Lilly plans to file in the first quarter of 2027. A standard review takes about ten months, so the first decision lands in late 2027 or early 2028, followed by pricing and coverage.
See the timeline →
Trials near you
Select your state to see studies with nearby sites, then open a study for its eligibility criteria and contact details from ClinicalTrials.gov.
11 active retatrutide studies · 2 accepting participants
| Study | Status | Phase | Sites |
|---|---|---|---|
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatoti… NCT07165028 · Metabolic Dysfunction-Associated Steatotic Liver Disease · Eli Lilly and Company | Recruiting | Phase 3 | 565 · 35 US states |
| Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight NCT07467447 · Obesity · Hudson Biotech | Recruiting | Phase 2 | 1 |
| Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With… NCT06383390 · Atherosclerotic Cardiovascular Disease (ASCVD) · Eli Lilly and Company | Closed to new participants | Phase 3 | 743 · 34 US states |
| Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequa… NCT06260722 · Diabetes Mellitus, Type 2 · Eli Lilly and Company | Closed to new participants | Phase 3 | 77 · 22 US states |
| Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe… NCT06297603 · Type 2 Diabetes · Eli Lilly and Company | Closed to new participants | Phase 3 | 76 · 16 US states |
| Retatrutide Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity NCT06662383 · Obesity · Eli Lilly and Company | Closed to new participants | Phase 3 | 65 · 22 US states |
| Retatrutide in the Maintenance of Weight Reduction in Individuals With Obesity NCT06859268 · Obesity · Eli Lilly and Company | Closed to new participants | Phase 3 | 53 · 21 US states |
| Retatrutide in Participants Who Have Obesity or Overweight and Chronic Low Back Pain NCT07035093 · Obesity · Eli Lilly and Company | Closed to new participants | Phase 3 | 40 · 14 US states |
| Retatrutide in Participants Without Type 2 Diabetes Who Have Obesity or Overweight NCT07357415 · Obesity · Eli Lilly and Company | Closed to new participants | Phase 3 | 35 · 14 US states |
| Retatrutide in Participants With Obesity or Overweight NCT07232719 · Obesity · Eli Lilly and Company | Closed to new participants | Phase 3 | 31 · 11 US states |
| Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Di… NCT06982859 · Diabetes Mellitus · Eli Lilly and Company | Closed to new participants | Phase 1 | 1 |
“Closed to new participants” studies are running but no longer enrolling. Each listing on ClinicalTrials.gov carries the eligibility criteria, the site list and a contact for enrollment. How trial participation works.
Options that do not provide access
Products sold as retatrutide are not the pharmaceutical product supplied in the trials.
Online vials
Sold as “research use only”. Unverified purity and amount, no medical oversight, and the FDA is issuing warning letters to sellers that name retatrutide.
Read about online vials →Compounding pharmacies
Compounders may only copy approved drugs. The July 2026 advisory vote covered six other peptides, and it changes nothing until a final rule.
Read about compounding pharmacies →Telehealth
Platforms can prescribe approved GLP-1 drugs such as tirzepatide and semaglutide today. None can prescribe retatrutide.
Read about telehealth →Read next
Retatrutide Cost & How to Get It
Every legitimate route to retatrutide today, open trials updated daily, Lilly's expanded access criteria, and what it may cost once approved.
Updated September 6, 2026
How to Sign Up for a Retatrutide Clinical Trial
Numbered TRIUMPH obesity trials are closed; open options include TRIUMPH-7 (low back pain) and the MASLD master protocol. How to find and enroll.
Updated July 25, 2026
Retatrutide FDA Approval Timeline 2026-2028
Lilly plans a Q1 2027 BLA filing. TRIUMPH-1, -2 and -3 have reported. Approval window late 2027–28.
Updated July 25, 2026
When Will Retatrutide Be Available?
Retatrutide is not yet available. Lilly plans a Q1 2027 BLA filing; FDA approval projected late 2027 to H1 2028, launch in 2028.
Updated July 25, 2026
Are Peptides Legal in 2026? Inside the FDA 503A Vote Result
The FDA's advisory committee recommended six of seven peptides on July 23-24, 2026 — against its own scientists. Why recommended still is not legal, and what it means for weight loss drugs.
Updated August 18, 2026
Grey Market Retatrutide: Risks, Dangers, and What You Should Know
Grey market retatrutide is unregulated, untested, and potentially dangerous. Here's what the data shows and how to access it safely.
Updated February 2026